Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Over the past 3 months, 6 analysts have published their opinion on 1Life Healthcare (NASDAQ:ONEM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Earnings Outlook For Astronics

Astronics (NASDAQ:ATRO) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Astronics will report an earnings per share (EPS) of $0.07.

Benzinga

8 Analysts Have This to Say About Rapid7

Rapid7 (NASDAQ:RPD) has observed the following analyst ratings within the last quarter:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Preview For DraftKings

DraftKings (NASDAQ:DKNG) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that DraftKings will report an earnings per share (EPS) of $-1.16.

Benzinga

Where Moderna Stands With Analysts

Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022

Upgrades

Benzinga

Pepgen Inc. IPOs Tomorrow, Here's What You Need To Know

PepGen Inc. (NASDAQ:PEPG) IPO will take place May, 06 on the NASDAQ exchange under the ticker PEPG. The company is offering shares at an expected price between $13.00 and $15.00 per share with an insider lock-up period of 180 days ending on November 02, 2022.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Preview: Wytec International, Inc Set To IPO Tomorrow

Wytec International, Inc (NASDAQ:WYTC) IPO will take place May, 06 on the NASDAQ exchange under the ticker WYTC. The company is offering shares at an expected price between $4.15 and $6.15 per share with an insider lock-up period of 180 days ending on November 02, 2022.

Benzinga

The RealReal's Return On Capital Employed Overview

According to Benzinga Pro data, during Q4, The RealReal (NASDAQ:REAL) posted sales of $145.12 million. Earnings were up 8.74%, but The RealReal still reported an overall loss of $52.20 million.

Benzinga

Garrett Motion's Return on Invested Capital Overview

Pulled from Benzinga Pro data, Garrett Motion (NASDAQ:GTX) showed a loss in earnings since Q4, totaling $88.00 million. Sales, on the other hand, increased by 4.52% to $901.00 million during Q1.

Benzinga

Ultralife's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Ultralife's (NASDAQ:ULBI) reported sales totaled $30.37 million. Despite a 85.73% increase in earnings, the company posted a loss of $161.00 thousand.

Benzinga

Looking Into West Bancorp's Return On Capital Employed

According to Benzinga Pro, during Q1, West Bancorp (NASDAQ:WTBA) earned $13.18 million, a 10.7% increase from the preceding quarter. West Bancorp's sales decreased to $26.22 million, a 2.72% change since Q4.

Benzinga

Option Care Health's Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Option Care Health (NASDAQ:OPCH) earned $30.27 million, a 59.88% increase from the preceding quarter. Option Care Health's sales decreased to $915.78 million, a 1.23% change since Q4.

Benzinga

ChipMOS Clocks 4% Revenue Growth in Q1; Margin Expands Amid Inflation, Supply Chain Woes

ChipMOS TECHNOLOGIES INC (NASDAQ:IMOS) reported first-quarter FY22 revenue growth of 4% year-on-year to $235 million. Revenue decreased by 1% Q/Q. The gross margin expanded 80 bps amid global inflation and supply chain constraints. Net non-operating income was $8 million versus $0.9 million a year ago. Earnings per basic ADS were $1.18 versus $0.92…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Lawson Products's Return on Invested Capital Overview

According to Benzinga Pro, during Q1, Lawson Products (NASDAQ:LAWS) earned $8.99 million, a 1250.58% increase from the preceding quarter. Lawson Products also posted a total of $117.88 million in sales, a 15.49% increase since Q4.

Benzinga

American Electric Power's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, American Electric Power (NASDAQ:AEP) earned $718.10 million, a 33.33% increase from the preceding quarter. American Electric Power also posted a total of $4.60 billion in sales, a 12.2% increase since Q4.

Benzinga

Keurig Dr Pepper's Return on Invested Capital Overview

According to Benzinga Pro, during Q1, Keurig Dr Pepper (NASDAQ:KDP) earned $585.00 million, a 30.6% increase from the preceding quarter. Keurig Dr Pepper's sales decreased to $3.08 billion, a 9.23% change since Q4.

Benzinga

Power Integrations's Return on Invested Capital Overview

According to Benzinga Pro, during Q1, Power Integrations (NASDAQ:POWI) earned $46.25 million, a 13.63% increase from the preceding quarter. Power Integrations also posted a total of $182.15 million in sales, a 5.5% increase since Q4.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pegasystems's Return on Invested Capital Insights

According to data from Benzinga Pro, during Q1, Pegasystems's (NASDAQ:PEGA) reported sales totaled $376.31 million. Despite a 98.98% increase in earnings, the company posted a loss of $379.00 thousand.

Benzinga

DexCom Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, DexCom (NASDAQ:DXCM) posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters.

Benzinga

Looking Into NovoCure's Return On Capital Employed

According to data from Benzinga Pro, during Q1, NovoCure's (NASDAQ:NVCR) reported sales totaled $137.55 million. Despite a 82.44% increase in earnings, the company posted a loss of $4.65 million.

Benzinga

Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Alnylam Pharmaceuticals's (NASDAQ:ALNY) reported sales totaled $213.26 million. Despite a 7.01% increase in earnings, the company posted a loss of $240.34 million.

Benzinga

Recap: Selecta Biosciences Q1 Earnings

Selecta Biosciences (NASDAQ:SELB) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Shenandoah's Return On Capital Employed Insights

Benzinga Pro data, Shenandoah (NASDAQ:SHEN) reported Q1 sales of $64.41 million. Earnings fell to a loss of $603.00 thousand, resulting in a 172.65% decrease from last quarter.

Benzinga

Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus

Inari Medical Inc's (NASDAQ:NARI) Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61 million. The increase over the prior year was driven by continued U.S. commercial expansion and new product introductions. The gross margin was 88.5% compared to 91.9% a year ago, modestly lower primarily…

1 … 600 601 602 603

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

387,664 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.